

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, DC 20549

---

**FORM 8-K**

---

**CURRENT REPORT**

**Pursuant to Section 13 OR 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): March 3, 2021**

---

**The Carlyle Group Inc.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or Other Jurisdiction  
of Incorporation)

**001-35538**  
(Commission  
File Number)

**45-2832612**  
(IRS Employer  
Identification No.)

**1001 Pennsylvania Avenue, NW**  
**Washington, DC**  
(Address of Principal Executive Offices)

**20004-2505**  
(Zip Code)

**(202) 729-5626**  
(Registrant's Telephone Number, Including Area Code)

**Not Applicable**  
(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock	CG	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

**Item 5.02**                    **Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On March 4, 2021, The Carlyle Group Inc. (the “Company”) issued a press release announcing that effective March 8, 2021, Derica Rice will join the Board of Directors of the Company as a Class II director. The appointment was approved by the Company's Board of Directors on March 3, 2021.

Mr. Rice, age 56, served as executive vice president of CVS Health and President of CVS Caremark, the pharmacy benefits management business of CVS Health, from March 2018 to February 2020. Previously, he held various executive positions at Eli Lilly and Company, most recently executive vice president of Global Services and chief financial officer from 2006 to 2017. Mr. Rice is currently a director of Bristol-Meyers Squibb Company, Target Corporation and The Walt Disney Company. Mr. Rice received his Bachelor of Science degree in Electrical and Electronics Engineering from Kettering University and an MBA from Indiana University.

No action has been taken at this time with respect to Mr. Rice’s committee appointments.

Mr. Rice will receive the annual compensation we provide to non-employee directors as described in the "Director Compensation" section of the Company's Annual Report on Form 10-K for the year ended December 31, 2019, filed with the Securities and Exchange Commission on February 12, 2020.

**Item 7.01**                    **Regulation FD Disclosure.**

A copy of the Company's press release regarding the matters described above has been furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Pursuant to General Instruction B.2 of Current Report on Form 8-K, the information in Item 7.01 of this Current Report on Form 8-K, including the press release attached hereto as Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. Furthermore, such information shall not be incorporated by reference into any filing or other document pursuant to the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing or document.

**Item 9.01**                    **Financial Statements and Exhibits**

**(d) Exhibits**

<b>Exhibit No.</b>	<b>Description</b>
99.1	<a href="#">Press Release, dated March 4, 2021.</a>
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**The Carlyle Group Inc.**

Date: March 4, 2021

By: /s/ Curtis L. Buser  
Name: Curtis L. Buser  
Title: Chief Financial Officer

### Carlyle Appoints Derica Rice as an Independent Director

Washington, DC, March 4, 2021 – Global investment firm The Carlyle Group Inc. (NASDAQ: CG) today announced the appointment of Derica Rice, former Executive Vice President of CVS Health Corporation and President of CVS Caremark, to serve as an Independent Director of its Board of Directors, effective March 8, 2021.

Rice joins Carlyle’s Board of Directors following a distinguished career in the healthcare and consumer-facing industry. Most recently, Rice served as Executive Vice President of CVS Health Corporation and President of CVS Caremark, the company’s pharmacy benefits management (PBM) business, where he oversaw all aspects of the business, including sales and account management, operations, mail service pharmacy and specialty pharmacy. Prior to joining CVS in 2018, Rice served as Executive Vice President of Global Services and Chief Financial Officer at Eli Lilly and Company. In this role, he oversaw all financial, business strategy, business development, IT and Six Sigma activities.

“We are delighted to welcome Derica to Carlyle’s Board of Directors and we look forward to his contributions as he brings great candor, diverse perspectives, and complementary skillsets to the board to help support the firm for accelerated growth,” said Carlyle Co-Chairmen Bill Conway and David Rubenstein.

“Carlyle is an incredible firm and highly regarded for decades by investors for its brand and reputation around the world,” said Derica Rice. “I am honored to join the Board during a period of growth and positioning for the future.”

Currently, Rice serves on the public boards of Bristol-Myers Squibb Company, Target Corporation, and The Walt Disney Company. He previously served on the Target board from 2007 to 2018, during which time he chaired the Audit and Finance Committee from 2015 to 2018.

Rice holds a master’s degree in business administration from Indiana University and a bachelor’s degree in electrical engineering from Kettering University.

#### About The Carlyle Group

The Carlyle Group (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across three business segments: Global Private Equity, Global Credit and Investment Solutions. With \$246 billion of assets under management as of December 31, 2020, Carlyle’s purpose is to invest wisely and create value on behalf of its investors, portfolio companies and the communities in which we live and invest. The Carlyle Group employs 1,825 people in 29 offices across five continents. Further information is available at [www.carlyle.com](http://www.carlyle.com). Follow The Carlyle Group on Twitter @OneCarlyle.

#### Media:

Leigh Farris  
Phone: +1 (212) 813-4815  
[leigh.farris@carlyle.com](mailto:leigh.farris@carlyle.com)

#### Public Market Investor Relations:

Daniel Harris  
Phone: +1 (212) 813-4527  
[daniel.harris@carlyle.com](mailto:daniel.harris@carlyle.com)